中药直肠滴注对CAP/CPPS患者炎症因子MCP-1及PDGF-BB表达的影响

摘要

目的 观察中药直肠滴注对慢性非细菌性前列腺炎/慢性盆腔疼痛综合征(CAP/CPPS)患者炎症因子单核细胞趋化因子-1 (MCP-1)及血小板衍生生长因子-BB (PDGF-BB)的影响,探讨其作用机制.方法 将CAP/CPPS患者(湿热夹瘀证)40例随机分为2组.治疗组20例子灌肠Ⅰ号方直肠滴入,对照组20例子邦列安纳米银抗菌水凝胶肛门给药.4周后对2组的疗效进行评价,观察治疗前后中医证候积分、美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)、前列腺液白细胞(EPS-WBC)计数及前列腺液中MCP-1、PDGF-BB水平的变化.结果 灌肠Ⅰ号方可显著降低中医证候评分,减少EPS-WBC计数,并降低MCP-1、PDGF-BB水平,但2组在总有效率、改善NIH-CPSI症状评分方面,差异无统计学意义.结论 调控炎症因子MCP-1及PDGF-BB可能是灌肠Ⅰ号方直肠滴注治疗CAP/CPPS的重要免疫机制之一.%Objective To study the effect of rectum instill Chinese herbal medicine on the expressions of inflammatory factors MCP-1 and PDGF-BB in CAP/CPPS, and explore its mechanism. Methods A total of 40 patients diagnosed as CAP/CPPS with the type of damp-heat and blood stasis were divide randomly into 2 groups, the trial group (20 patients) treated with Enema I for 4 weeks and the control group (20 patients) with Bangliean in the same way. The efficacy was evaluated by syndrome index of Chinese medicine for prostatitis, NIH chronic prostatitis symptom index (NIH-CPSI), the count of EPS-WBC and the expression of MCP-1 and PDGF-BB. Results After treatment, syndrome index of Chinese medicine for prostatitis, the count of EPS-WBC, the expression of MCP-1 and PDGF-BB decreased significantly in the trial group, but the overall response rate and NIH-CPSI had no significant difference. Conclusion Down-regulation inflammatory factors MCP-1 and PDGF-BB may be the important immunological mechanism of Enema I in treating CAP/CPPS patients by rectum instill.